Metabolic Peptides

5-Amino-1-Methylquinolinium · NNMT Inhibitor

A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.

NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin

A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.

Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191

AOD-9604 is a modified human-growth-hormone fragment investigated for obesity and fat metabolism. Its obesity development program did not establish efficacy, and current regulatory sources identify major safety and quality gaps for unapproved or compounded products.

AM833 · NN9838

Investigational long-acting amylin analogue. REDEFINE 1 included a Phase 3 cagrilintide-only arm; Novo reports 11.8% mean weight loss versus 2.3% with placebo at 68 weeks using an on-treatment estimand. Dedicated RENEW Phase 3 monotherapy trials have started. Cagrilintide is also a CagriSema component.

Cagrilintide-Semaglutide · NNC0174-0833

Investigational fixed-dose cagrilintide plus semaglutide combination. Novo filed a US obesity NDA in December 2025. Its sponsor-reported REDEFINE 4 head-to-head trial missed non-inferiority versus tirzepatide; September 2026 REIMAGINE 5 and REDEFINE 9 toplines address different populations and doses. A filing and positive toplines are not FDA approval.

RG-6912

A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.

XW003 · Sciwind GLP-1

A long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.

Victoza · Saxenda · NN2211

The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.

AMG 133 · maridebart cafraglutide

A bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism. Unique mechanism opposite to tirzepatide. The published Phase 2 trial (NCT05669599) showed up to ~16% weight loss at 52 weeks with once-monthly dosing. MARITIME Phase 3 program ongoing.

IBI362 · LY3305677 · Xinermei

Mazdutide is a GLP-1 and glucagon receptor dual agonist with randomized weight-management and type 2 diabetes data, mostly from Chinese trials plus one published US phase 2 trial. Innovent reports approval in China for specified adult weight-management and diabetes indications; this does not establish US or EU approval or an indication for other conditions.

LY3502970 · OWL833

Oral small-molecule GLP-1 receptor agonist approved by the US FDA on 1 April 2026 as Foundayo for chronic weight management in eligible adults. The July 2026 FDA label advises against use with another GLP-1 agonist and lists specific drug interactions. Type 2 diabetes remains an unapproved use, despite published Phase 3 ACHIEVE trials.

ALT-801 · GLP-1/Glucagon Dual Agonist

Investigational GLP-1/glucagon dual agonist. The published IMPACT Phase 2b trial met its 24-week MASH-resolution endpoint but not its fibrosis-improvement co-primary endpoint. Phase 3 PERFORMA in MASH has begun. Altimmune also reported positive Phase 2 RECLAIM alcohol-use-disorder toplines in July 2026; these sponsor results are not yet a peer-reviewed paper or FDA approval.

Pfizer GLP-1 · Monthly GLP-1

Pfizer's once-monthly GLP-1 receptor agonist peptide (Metsera MET097 lineage). The once-monthly Phase 2b (SOLIS-1, NCT07575932) is recruiting with no reported results yet, and the molecule has no published efficacy data. A Phase 3 program (VESPER-4/5/6) is enrolling, positioning it as a potential long-acting alternative to weekly GLP-1 therapies.

LY3437943 · GGG Triple Agonist

Investigational GIP/GLP-1/glucagon receptor agonist. A phase 3 diabetes trial is published; Lilly has also released topline phase 3 obesity results from TRIUMPH-1, -2, -3 and -4. These sponsor announcements are not peer-reviewed efficacy papers. Lilly plans an FDA submission in early 2027; no approval has been established.

Ozempic · Wegovy · Rybelsus +1

A GLP-1 receptor agonist with US approvals that differ by product and route: diabetes products for type 2 diabetes, Wegovy for weight and cardiovascular risk reduction, and Wegovy injection under accelerated approval for noncirrhotic MASH with F2-F3 fibrosis in adults.

ERR agonist 332 · Exercise mimetic compound

A small molecule ERR (Estrogen-Related Receptor) agonist developed at Saint Louis University. Preclinical studies suggest exercise-mimetic properties, but no human data exists. Represents early-stage research into pharmacologically activating exercise pathways.

BI 456906 · BI-456906 · ZP6590

Investigational GLP-1/glucagon dual agonist. Published Phase 3 SYNCHRONIZE-1 showed 13.0% versus 5.4% placebo weight reduction at 76 weeks under the treatment-regimen estimand. SYNCHRONIZE-MASLD met liver-fat and weight endpoints at 48 weeks, but measured liver fat by MRI rather than biopsy resolution or fibrosis. Neither study establishes cardiovascular benefit.

LY3298176 · Mounjaro · Zepbound

A dual GIP/GLP-1 receptor agonist with US product-specific approvals: Mounjaro for type 2 diabetes in adults and children aged 10 years and older, and Zepbound for adult weight reduction and moderate-to-severe obstructive sleep apnea in adults with obesity. SURPASS-CVOT established cardiovascular noninferiority to dulaglutide, without superiority.

Viking 2735

A dual GLP-1/GIP receptor agonist from Viking Therapeutics with both subcutaneous and oral formulations. Phase 2 VENTURE trial showed 14.7% weight loss at 13 weeks (SC) and 12.2% (oral). Phase 3 VANQUISH-1 enrolled 4,500 patients.